Combining surgery and chemotherapy for invasive bladder cancer: current and future directions

References

• Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J. Clin. 55(1), 10–30 (2005).
   PubMed Web of Science ®Google Scholar
• Messing EM, Young TB, Hunt VB et al. Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology 45(3), 387–397 (1995).
   PubMed Web of Science ®Google Scholar
• Lerner SP, DG Skinner. Radical cystectomy for bladder cancer. In: Comprehensive Textbook of Genitourinary Oncology. PT Scardino (Ed.). Lippincott Williams & Wilkins, PA, USA, 425–447 (1999).
   Google Scholar
• Skinner DG. Management of invasive bladder cancer: a meticulous pelvic node dissection can make a difference. J. Urol. 128(1), 34–36 (1982).
   PubMed Web of Science ®Google Scholar
• Lerner SP, Skinner DG, Lieskovsky G et al. The rationale for en bloc pelvic lymph node dissection for bladder cancer patients with nodal metastases: long-term results. J. Urol. 149(4), 758–765 (1993).
   PubMed Web of Science ®Google Scholar
• Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol. 19(3), 666–675 (2001).
   PubMed Web of Science ®Google Scholar
• Mills RD, Turner WH, Fleischmann A, Markwalder R, Thalmann GN, Studer UE. Pelvic lymph node metastases from bladder cancer: outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy. J. Urol. 166(1), 19–23 (2001).
   PubMed Web of Science ®Google Scholar
• Vieweg J, Gschwend JE, Herr HW, Fair WR. Pelvic lymph node dissection can be curative in patients with node positive bladder cancer. J. Urol.161 (2), 449–454 (1999).
   PubMed Web of Science ®Google Scholar
• Leissner J, Hohenfellner R, Thuroff JW, Wolf HK. Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis. BJU Int. 85(7), 817–823 (2000).
   PubMed Web of Science ®Google Scholar
• Herr HW, Bochner BH, Dalbagni G, Donat SM, Reuter VE, Bajorin DF. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J. Urol. 167(3), 1295–1298 (2002).
   PubMed Web of Science ®Google Scholar
• Herr HW. Superiority of ratio based lymph node staging for bladder cancer. J. Urol. 169(3), 943–945 (2003).
   PubMed Web of Science ®Google Scholar
• Stein JP, Cai J, Groshen S, Skinner DG. Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: concept of lymph node density. J. Urol. 170(1), 35–41 (2003).
   PubMed Web of Science ®Google Scholar
• Vazina A, Dugi D, Shariat SF, Evans J, Link R, Lerner SP. Stage specific lymph node metastasis mapping in radical cystectomy specimens. J. Urol. 171(5), 1830–1834 (2004).
   PubMed Web of Science ®Google Scholar
• Stein JP, Skinner DG. The role of lymphadenectomy in high-grade invasive bladder cancer. Urol. Clin. North Am. 32(2), 187–197 (2005).
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Yagoda A, Scher HI et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64(12), 2448–2458 (1989).
   PubMed Web of Science ®Google Scholar
• Loehrer PJ Sr., Einhorn LH, Elson PJ et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a co-operative group study. J. Clin. Oncol. 10(7), 1066–1073 (1992).
   PubMed Web of Science ®Google Scholar
• Logothetis CJ, Dexeus FH, Finn L et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J. Clin. Oncol. 8(6), 1050–1055 (1990).
   PubMed Web of Science ®Google Scholar
• Gabrilove JL, Jakubowski A, Scher H et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N. Engl. J. Med. 318(22), 1414–1422 (1988).
   PubMed Web of Science ®Google Scholar
• Sternberg CN, de Mulder PH, Schornagel JH et al. Randomized Phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J. Clin. Oncol. 19(10), 2638–2646 (2001).
   PubMed Web of Science ®Google Scholar
• von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter Phase III study. J. Clin. Oncol. 18(17), 3068–3077 (2000).
   PubMed Web of Science ®Google Scholar
• Bajorin DF, Dodd PM, Mazumdar M et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J. Clin. Oncol. 17(10), 3173–3181 (1999).
   PubMed Web of Science ®Google Scholar
• Saxman SB, Propert KJ, Einhorn LH et al. Long-term follow-up of a Phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a co-operative group study. J. Clin. Oncol. 15(7), 2564–2569 (1997).
   PubMed Web of Science ®Google Scholar
• Winquist EW, Kirchner TS, Segal R. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J. Urol.171(2 Pt 1), 561–569 (2004).
   PubMed Web of Science ®Google Scholar
• Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349(9), 859–866 (2003).
   PubMed Web of Science ®Google Scholar
• Malmstrom PU, Rintala E, Wahlqvist R, Hellstrom P, Hellstem S, Hannisdal E. Five-year follow-up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Co-operative Bladder Cancer Study Group. J. Urol. 155(6), 1903–1906 (1996).
   PubMed Web of Science ®Google Scholar
• Sherif A. Neoadjuvant platinum based combination chemotherapy improves overall survival in patients with locally advanced bladder cancer. A meta-analysis of two nordic collaborative studies of 620 patients. J. Urol. 169, 307 (2003).
   Google Scholar
• Sherif A, Holmberg L, Rintala E et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur. Urol. 45(3), 297–303 (2004).
   PubMed Web of Science ®Google Scholar
• Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 361, 1927–1934 (2003).
   PubMed Web of Science ®Google Scholar
• Shipley WU, Kaufman DS, Tester WJ et al. Overview of bladder cancer trials in the Radiation Therapy Oncology Group. Cancer 97(Suppl. 8), S2115–S2119 (2003).
   PubMed Web of Science ®Google Scholar
• Sauer R. Muscle-invasive bladder cancer: transurethral resection and radiochemotherapy as an organ-sparing treatment option. In: Carcinoma of the Bladder. Brady LW (Ed.). Springer, Heidelberg, Germany, 205–214 (1998).
   Google Scholar
• Aparicio AM, Elkhouiery AB, Quinn DI. The current and future application of adjuvant systemic chemotherapy in patients with bladder cancer following cystectomy. Urol. Clin. North Am. 32(2), 217–230 (2005).
   PubMed Web of Science ®Google Scholar
• Logothetis CJ, Johnson DE, Chong C et al. Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update. J. Clin. Oncol. 6(10), 1590–1596 (1988).
   PubMed Web of Science ®Google Scholar
• Skinner DG, Daniels JR, Russel CA et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J. Urol. 145(3), 459–467 (1991).
   PubMed Web of Science ®Google Scholar
• Stockle M, Meyenburg W, Wellek S et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J. Urol.. 148(2 Pt 1), 302–307 (1992).
   PubMed Web of Science ®Google Scholar
• Freiha FJ, Reese FM, Torti A. randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J. Urol. 155(2), 495–500 (1996).
   PubMed Web of Science ®Google Scholar
• Studer UE, Bacchi M, Biedermann C et al. Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J. Urol. 152(1), 81–84 (1994).
   PubMed Web of Science ®Google Scholar
• Bono AV, Benvenuti C, Reali L et al. Adjuvant chemotherapy in advanced bladder cancer. Italian Uro-Oncologic Co-operative Group. Prog. Clin. Biol. Res. 303, 533–540 (1989).
   PubMedGoogle Scholar
• Stockle M, Meyenburg W, Wellek S et al. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J. Urol. 153(1), 47–52 (1995).
   PubMed Web of Science ®Google Scholar
• Vaughn DJ, Malkowicz SB. Neoadjuvant chemotherapy in patients with invasive bladder cancer. Urol. Clin. North Am. 32(2), 231–237 (2005).
   PubMed Web of Science ®Google Scholar
• Lehmann J, Retz M, Wiemers C. et al. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter Phase III trial (AUO-AB 05/95). J. Clin. Oncol. 23(22), 4963–4974 (2005).
   PubMed Web of Science ®Google Scholar
• Millikan R, Dinney C, Swanson D et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J. Clin. Oncol. 19(20), 4005–4013 (2001).
   PubMed Web of Science ®Google Scholar
• Fisher B, Bryant J, Wolmark N et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J. Clin. Oncol. 16(8), 2672–2685 (1998).
   PubMed Web of Science ®Google Scholar
• Herr H, Faulkner JR, Grossman HB et al. Surgical factors influence bladder cancer outcomes: a co-operative group report. J. Clin. Oncol. 22(14), 2781–2789 (2004).
   PubMed Web of Science ®Google Scholar
• Esrig D, Elmajain D, Groshen S et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med. 331(19), 1259–1264 (1994).
   PubMed Web of Science ®Google Scholar
• Cote RJ, Esrig D, Groshen S, Jones PA, Skinner DG. p53 and treatment of bladder cancer. Nature 385(6612), 123–125 (1997).
   PubMed Web of Science ®Google Scholar
• Cote RJ, Dunn MD, Chatterjee SJ et al. Elevated and absent pRb expression is associated with bladder cancer progression and has co-operative effects with p53. Cancer Res. 58(6), 1090–1094 (1998).
   PubMed Web of Science ®Google Scholar
• Herr HW, Bajorin DF, Scher HI, Cordon-Cardo C, Reuter VE. Can p53 help select patients with invasive bladder cancer for bladder preservation? J. Urol. 161(1), 20–23 (1999).
   PubMed Web of Science ®Google Scholar
• Shariat SF, Tokunaga H, Zhou J et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J. Clin. Oncol. 22(6), 1014–1024 (2004).
   PubMed Web of Science ®Google Scholar
• Chatterjee SJ, Datar R, Youssefzadeh D et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J. Clin. Oncol. 22(6), 1007–1013 (2004).
   PubMed Web of Science ®Google Scholar
• Hussain SA, Ganasan R, Hiller L et al. BCL2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladder. Oncol. Rep. 10(3), 571–576 (2003).
   PubMed Web of Science ®Google Scholar
• Guan KP, Ye HY, Yan Z, Wang Y, Hou SK. Serum levels of endostatin and matrix metalloproteinase-9 associated with high stage and grade primary transitional cell carcinoma of the bladder. Urology 61(4), 719–723 (2003).
   PubMed Web of Science ®Google Scholar
• Wu W, Shu X, Hovsepyan H, Mosteller RD, Broek D. VEGF receptor expression and signaling in human bladder tumors. Oncogene 22(22), 3361–3370 (2003).
   PubMed Web of Science ®Google Scholar
• Bartoletti R, Cai T, Nesi G, Sardi I, Rizzo M. Qualitative and quantitative analysis of angiogenetic factors in transitional cell bladder carcinoma: relationship with clinical course at 10 years follow-up. Oncol. Rep. 14(1), 251–255 (2005).
   PubMed Web of Science ®Google Scholar
• Wallace DM, Raghaven D, Kelly KA et al. Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J. Urol. 67(6), 608–615 (1991).
   Google Scholar
• Martinez-Pineiro JA, Gonzalez Martin M, Arocena F et al. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized Phase III study. J. Urol. 153(3 Pt 2), 964–973 (1995).
   PubMed Web of Science ®Google Scholar
• Coppin CM, Gospodarowicz MK, James K et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 14(11), 2901–2907 (1996).
   PubMed Web of Science ®Google Scholar
• Sherif A, Rintala E, Mestad O et al. Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer – Nordic cystectomy trial 2. Scand. J. Urol. Nephrol. 36(6), 419–425 (2002).
   PubMed Web of Science ®Google Scholar
• Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet 354, 533-540 (1999).
   Google Scholar
• Bassi P, Pappagallo G. Neoadjuvant M-VAC chemotherapy of invasive bladder cancer: the GUONE multicenter Phase III trial. Eur. Urol. 33(Suppl. 1), 142 (1998).
   Google Scholar
• Abol-Enein H, El-Mekresh M, El-Baz M. Neoadjuvant chemotherapy in the treatment of invasive transitional bladder cancer. A controlled prospective randomized study. BJU Int. 80(Suppl. 2), 49 (1997).
   Google Scholar
• Sengelov L, von der Masse H, Lundbeck F et al. Neoadjuvant chemotherapy with cisplatin and methotrexate in patients with muscle-invasive bladder tumours. Acta. Oncol. 41(5), 447–456 (2002).
   PubMed Web of Science ®Google Scholar